Sexual and reproductive health
Melanotan-2 (MT-2)
Also called MT-II, MT-2
per administration
A human trial worked out how much to take and how often, so a dosing schedule is shown.
Work out your draw
These numbers are a starting point — change any of them.
- Concentration
- 3.33mg/mL
- Volume per draw
- 0.21mL
- Units to dial
- 21
- Doses per cartridge
- 14
Vial label
Copy this into your label printer.
Published research contexts for Melanotan-2 (MT-2) describe 0.7–2.1 mg per administration. Descriptive only, not a recommendation.
Roughly 1–2 hours, but poorly characterized; published estimates vary.
The one human dosing source is a three-subject 1996 safety pilot (Dorr), not a dose-ranging trial, so the tier-A grade and the schedule below both rest on an n=3 sample and should be read as provisional.
Dosing schedule
How Melanotan-2 (MT-2) is commonly stepped up, for reference only.
These are commonly-discussed research protocols shared for educational reference. This is not medical advice and is not a substitute for guidance from a qualified professional.
| Phase | Amount | Frequency | Route |
|---|---|---|---|
| Reported rangeA melanocortin agonist. These amounts come from a three-subject 1996 pilot; the sample is far too small to fix a schedule. | 0.01–0.03 mg/kg (about 0.7–2.1 mg for a 70 kg adult) | Once daily, Monday–Friday | SubQ |
Modelled level — 5 days on, 2 off
1× is the peak after a single dose.
- Steady-state peak
- 1.00× single dose
- Time to steady state
- 8hours
- Administrations
- 5/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- Dorr RT et al., Life Sci 1996;58:1777A three-subject safety pilot of melanotan-II given subcutaneously at 0.01–0.03 mg/kg on a weekday schedule.